Prudential PLC Acquires 377 Shares of Zoetis Inc. (NYSE:ZTS)

Prudential PLC increased its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 1.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,260 shares of the company’s stock after acquiring an additional 377 shares during the quarter. Prudential PLC’s holdings in Zoetis were worth $6,565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Bell Private Wealth Management LLC increased its stake in Zoetis by 222.5% during the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after purchasing an additional 89 shares in the last quarter. Independence Bank of Kentucky increased its stake in Zoetis by 371.4% during the 4th quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Private Wealth Management Group LLC bought a new stake in shares of Zoetis in the fourth quarter worth approximately $33,000. Ramirez Asset Management Inc. bought a new stake in shares of Zoetis in the third quarter worth approximately $35,000. Finally, Gladius Capital Management LP bought a new stake in shares of Zoetis in the fourth quarter worth approximately $40,000. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. HSBC dropped their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. The Goldman Sachs Group dropped their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. Finally, Barclays dropped their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $211.75.

Check Out Our Latest Analysis on Zoetis

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.16% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS traded up $0.14 during trading hours on Friday, hitting $176.92. 1,819,455 shares of the stock traded hands, compared to its average volume of 2,107,329. The company has a market cap of $80.73 billion, a price-to-earnings ratio of 34.08, a price-to-earnings-growth ratio of 2.75 and a beta of 0.88. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The stock has a 50 day moving average price of $164.77 and a 200 day moving average price of $179.64.

Zoetis (NYSE:ZTSGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion for the quarter, compared to analysts’ expectations of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter last year, the business posted $1.31 earnings per share. Sell-side analysts forecast that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend is Thursday, July 18th. Zoetis’s payout ratio is currently 33.14%.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Articles

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.